The Microvasive® Needle Knife Sphincterotome is indicated for use in transendoscopic sphincterotomy of the Papilla of Vater and/or the Sphincter of Oddi. The Microvasive Needle Knife can also be used to cannulate and inject contrast medium.

Device Description

Not Found

AI/ML Overview

This document is a 510(k) summary for the Microvasive® Needle Knife Sphincterotome. It outlines the manufacturer's claim of substantial equivalence to previously marketed devices rather than providing a detailed study proving the device meets specific acceptance criteria in the manner requested by the prompt.

Therefore, much of the requested information regarding "acceptance criteria" and "study data" for an AI/device performance evaluation is not applicable here because this document describes a traditional medical device (a sphincterotome) undergoing a 510(k) clearance process, not an AI or software as a medical device (SaMD).

However, I can extract the relevant information from the document that touches upon performance and equivalence.

Here's the breakdown of what can be extracted and what information is not present based on the provided text:

1. A table of acceptance criteria and the reported device performance

Acceptance Criteria (Inferred from 510(k) Process)	Reported Device Performance (from document)
Safety: Biocompatibility	Biocompatibility assessment performed on patient- and fluid-contact materials with satisfactory results.
Safety: Sterilization	Sterilized using ethylene oxide gas using the AAMI protocol.
Safety: Pyrogenicity	Pyrogenicity testing performed periodically to monitor bacterial endotoxin levels.
Performance: Functional Equivalence	Laboratory testing performed to verify safety and performance. Believed to be substantially equivalent in design and materials to predicate devices.
Intended Use: As specified	Indicated for transendoscopic sphincterotomy of the Papilla of Vater and/or the Sphincter of Oddi. Can also be used to cannulate and inject contrast medium.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

Not Applicable. The document describes "laboratory testing" and a "biocompatibility assessment," but it does not specify a "test set" in the context of clinical trial or AI model validation. It's a medical device clearance, not a data-driven performance study in the way the prompt implies.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

Not Applicable. This is not an AI or diagnostic device where expert ground truth for a test set is established.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Not Applicable.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not Applicable. This is a physical medical device, not an AI-assisted diagnostic tool.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Not Applicable.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

Not Applicable. The "ground truth" for this device's clearance would be its compliance with material standards, sterilization protocols, and functional performance in laboratory settings, as well as its similarity to previously cleared predicate devices.

8. The sample size for the training set

Not Applicable. This is not an AI model requiring a training set.

9. How the ground truth for the training set was established

Not Applicable.

Summary of what the document does provide regarding device performance:

The document focuses on establishing substantial equivalence to existing legally marketed devices (Microvasive® Rapid Exchange Sphincterotome and Ultratome XL™ Triple Lumen Sphincterotome).

Key points from the document regarding performance:

Laboratory testing: Stated that "Laboratory testing regarding characteristics was performed on the Microvasive® Needle Knife Sphincterotome to verify its safety and performance." However, no specific performance metrics or detailed results from this testing are provided in the summary.
Biocompatibility: "A biocompatibility assessment was performed on the patient- and fluid-contact materials of the Microvasive® Needle Knife Sphincterotome with satisfactory results."
Sterilization: The device "will be sterilized using ethylene oxide gas using the AAMI protocol for ethylene oxide sterilization."
Pyrogenicity: "Pyrogenicity testing will be performed on a periodic basis to monitor bacterial endotoxin levels."
Conclusion: The manufacturer "believes that Microvasive® Needle Knife Sphincterotome is substantially equivalent... A comparison of the descriptive characteristics of these products demonstrate the Microvasive® Needle Knife Sphincterotome is equivalent in its indications for use, while being very similar in design and materials."

In essence, this 510(k) summary asserts that the new device is safe and effective by demonstrating its similarities to already approved devices and by confirming basic safety aspects through laboratory tests, rather than providing a detailed study with specific performance metrics against a defined acceptance criterion.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows handwritten text that appears to be a combination of letters and numbers. The first line reads 'K973826', and the second line reads '1 of 2'. The handwriting is somewhat rough, giving the text a casual and informal appearance.

SECTION 9 510(K) SUMMARY

DEC - 5 1997

FOI RELEASABLE

Pursuant to §513(i)(3)(A) of the Food, Drug, and Cosmetic Act, Boston Scientific Corporation is required to submit with this Premarket Notification "...adequate summary of any information respecting safety and effectiveness or state that such information will be made available upon request of any person." Boston Scientific Corporation chooses to submit a summary of information respecting safety and effectiveness.

➤ COMMON/USUAL NAMES:	Sphincterotome
➤ TRADE/PROPRIETARY NAME:	None at this time
➤ CLASSIFICATION NAME &DEVICE CLASSIFICATION:	Class II
	Name	Number	21 CFR Ref
	Endoscopic ElectrosurgicalUnit and Accessories.	78 KNS	876.4300
➤ DEVICE PANEL/BRANCH:	Gastroenterology-Urology (GU)Gastro-Renal (GRDB)
➤ OWNER/OPERATOR:	Boston Scientific CorporationOne Boston Scientific PlaceNatick, MA 01760
➤ CONTACT PERSON:	Daniel J. Dillon, Senior Regulatory Affairs Specialist

INDICATIONS FOR USE

The Microvasive® Needle Knife Sphincterotome is indicated for use in transendoscopic sphincterotomy of the Papilla of Vater and/or the Sphincter of Oddi.

Contraindications

Contraindications for this device are those specific to endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (ES).

{1}------------------------------------------------

COMPLICATIONS

Possible complications include, but may not be limited to: pancreatitis; perforation; hemorrhage, hematoma, cholangitis; stone impaction; septicemia/infection; and allergic reaction to contrast medium

SUBSTANTIAL EQUIVALENCE

Boston Scientific Corporation believes that the Microvasive® Needle Knife Sphincterotome is substantially .equivalent to the currently-marketed Microvasive® Rapid Exchange Sphincterotome and Ultratome XLTM Triple Lumen Sphincterotome.

Performance Characteristics

Laboratory testing regarding characteristics was performed on the Microvasive® Needle Knife Sphincterotome to verify its safety and performance. A biocompatibility assessment was performed on the patient- and fluid-contact materials of the Microvasive® Needle Knife Sphincterotome with satisfactory results.

Packaging, Sterilization, And Pyrogenicity

The Microvasive® Needle Knife Sphincterotome will be sterile in a tray sealed with a Tyvek lid. The Microvasive® Needle Knife Sphincterotome will be sterilized using ethylene oxide gas using the AAMI protocol for ethylene oxide sterilization. Pyrogenicity testing will be performed on a periodic basis to monitor bacterial endotoxin levels.

CONCLUSION

Boston Scientific Corporation believes that Microvasive® Needle Knife Sphincterotome is substantially equivalent to the currently-marketed Microvasive® Rapid Exchange Sphincterotome and Ultratome XLTM Triple Lumen Sphincterotome. A comparison of the descriptive characteristics of these products demonstrate the Microvasive® Needle Knife Sphincterotome is equivalent in its indications for use, while being very similar in design and materials. In addition, Boston Scientific Corporation has presented laboratory testing and biocompatibility information. The information presented provides assurance that the Microvasive® Needle Knife Sphincterotome will meet the minimum requirements that are considered acceptable for its intended use.

{2}------------------------------------------------

Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular emblem with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing right, stacked on top of each other.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

DEC - 5 1997

Mr. Daniel J. Dillon Senior Regulatory Affairs Specialist Boston Scientific Corporation One Boston Scientific Place Natick, Massachusetts 01760-1537

Re: K973826 Microvasive® Needle Knife Sphincterotome Dated: October 3, 1997 Received: October 7, 1997 Regulatory class: II 21 CFR §876.4300/Product code 78 KNS

Dear Mr. Dillon:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic OS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus. permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807,97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours.

h. William Yu

Lillian Yin, Ph.D. Director, Division of Reproductive, Abdominal, Ear, Nose and Throat, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

{3}------------------------------------------------

510(k) Number:

Fo Be Determined K973826

Device Name:

Microvasive® Needle Knife Sphincterotome

Indication for Use:

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Robert R. Satting/

(Division Sign-Off) Division of Reproductive, Abdominal, ENT, and Radiological Devices 510(k) Number

Prescription Use
(Per 21 CFR 801.109)

Over-The-Counter Use_

Regulation Number and Section

§ 876.4300 Endoscopic electrosurgical unit and accessories.

(a)
Identification. An endoscopic electrosurgical unit and accessories is a device used to perform electrosurgical procedures through an endoscope. This generic type of device includes the electrosurgical generator, patient plate, electric biopsy forceps, electrode, flexible snare, electrosurgical alarm system, electrosurgical power supply unit, electrical clamp, self-opening rigid snare, flexible suction coagulator electrode, patient return wristlet, contact jelly, adaptor to the cord for transurethral surgical instruments, the electric cord for transurethral surgical instruments, and the transurethral desiccator.(b)
Classification. Class II (performance standards).